Results 151 to 160 of about 36,113 (205)

The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease. [PDF]

Front Immunol
Rao L, Liao J, Guo X, Miu Q, Zheng Y, Xun W.   +5 more
europepmc   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, Volume 56, Issue 6, Page 925-932, June 2026.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

Electrocardiographic Alterations Combined with Hematological, Biochemical, and Metabolic Profiles Predict Prognosis in Kawasaki Disease. [PDF]

J Cardiovasc Dev Dis
Wang Q, Li W, Wan J, Wei L, Xia Y, Hua Y, Zhou K, Qie D, Li W, Li Y.   +9 more
europepmc   +1 more source

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

Hepatology Research, Volume 56, Issue 6, Page 887-902, June 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related ...
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida   +44 more
wiley   +1 more source

Tocilizumab for the Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease in Children: Two Case Reports and Literature Review. [PDF]

J Inflamm Res
Wu LE, Huang CL, Wei JY, Lu SL.
europepmc   +1 more source

Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma with double‐hit MYC and BCL2 or BCL6 and triple hit

Histopathology, Volume 88, Issue 7, Page 1324-1347, June 2026.
Diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma (DLBCL/HGBCL) is a mature aggressive B‐cell lymphoma. This article performed a comprehensive clinicopathological and transcriptomic analyses of this lymphoma category. Aims Diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma (DLBCL/HGBCL) with MYC and BCL2 rearrangements (double‐hit lymphoma
Masashi Miyaoka, Joaquim Carreras, Yara Yukie Kikuti, Haruka Ikoma, Shunsuke Nagase, Atsushi Ito, Makoto Orita, Hiroshi Kawada, Rika Sakai, Yasuharu Sato, Midori Filiz Nishimura, Kunihiro Tsukasaki, Shuji Momose, Yoshihiro Kameoka, Masahiro Yoshida, Akira Satou, Seiichi Kato, Naoki Oishi, Akio Saito, Ken Sadahira, Yohei Masugi, Naoya Nakamura   +21 more
wiley   +1 more source

Anakinra use in pediatric kawasaki disease: inflammation control, coronary artery outcomes, and safety. [PDF]

Pediatr Rheumatol Online J
Kolahdoozan M, Kabiri F, Biyabanaki A, Shafiee F.   +3 more
europepmc   +1 more source

Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study

International Journal of Urology, Volume 33, Issue 6, June 2026.
ABSTRACT Objective This study aimed to evaluate the clinical relevance of early relative dose intensity (eRDI) during enfortumab vedotin (EV) monotherapy in patients with metastatic urothelial carcinoma (mUC) based on a Japanese real‐world multicenter cohort. Methods We retrospectively analyzed 119 patients with mUC who received EV.
Yuki Endo, Yuma Sakura, Go Kaneko, Nozomi Hayakawa, Daiki Ikarashi, Ryo Yamashita, Suguru Shirotake, Wataru Obara, Yukihiro Kondo, Eiji Kikuchi   +9 more
wiley   +1 more source